Valuation Update With 7 Day Price Move • 49m
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩2,035, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 16x in the Life Sciences industry in South Korea. Total loss to shareholders of 21% over the past three years. Valuation Update With 7 Day Price Move • Jun 24
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₩1,817, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 15x in the Life Sciences industry in South Korea. Total loss to shareholders of 34% over the past three years. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩2,430, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 20x in the Life Sciences industry in South Korea. Total loss to shareholders of 20% over the past three years. New Risk • May 27
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (₩58.9b market cap, or US$39.0m). New Risk • May 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.3% net profit margin). Market cap is less than US$100m (₩71.2b market cap, or US$47.8m). Announcement • Feb 26
Green Lifescience Co., Ltd., Annual General Meeting, Mar 26, 2026 Green Lifescience Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 84, yeosusandan 2-ro, jeollanam-do, yeosu South Korea Buy Or Sell Opportunity • Jun 11
Now 32% overvalued after recent price rise Over the last 90 days, the stock has risen 145% to ₩4,065. The fair value is estimated to be ₩3,077, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Earnings per share has declined by 42%. New Risk • May 28
New major risk - Revenue and earnings growth Earnings have declined by 41% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩77.0b market cap, or US$56.0m). New Risk • May 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩43.1b market cap, or US$31.3m). Valuation Update With 7 Day Price Move • May 21
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to ₩2,205, the stock trades at a trailing P/E ratio of 27.6x. Average trailing P/E is 18x in the Life Sciences industry in South Korea. Total loss to shareholders of 46% over the past three years. Announcement • Feb 27
Green Lifescience Co., Ltd., Annual General Meeting, Mar 27, 2025 Green Lifescience Co., Ltd., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 84, yeosusandan 2-ro, jeollanam-do, yeosu South Korea New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩34.8b market cap, or US$24.2m). New Risk • Aug 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (₩34.3b market cap, or US$25.1m). New Risk • Nov 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₩48.9b market cap, or US$37.5m). Announcement • Aug 23
Green Lifescience Co., Ltd. (KOSDAQ:A114450) announces an Equity Buyback for KRW 2,000 million worth of its shares. Green Lifescience Co., Ltd. (KOSDAQ:A114450) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its shares, pursuant the contract with Yuanta Securities Korea Co., Ltd. The purpose of the program is stock price stability and shareholder value enhancement. The program will expire on March 6, 2024. As of August 21, 2023, the company had no shares in treasury within scope available for dividend and no shares in treasury through other repurchase. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Feb 22
KPX Lifescience.Co.,Ltd., Annual General Meeting, Mar 18, 2021 KPX Lifescience.Co.,Ltd., Annual General Meeting, Mar 18, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Feb 17
New 90-day low: ₩9,330 The company is down 60% from its price of ₩23,250 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period. Is New 90 Day High Low • Jan 31
New 90-day low: ₩9,580 The company is down 1.0% from its price of ₩9,700 on 02 November 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 16% over the same period. Is New 90 Day High Low • Nov 06
New 90-day high: ₩12,550 The company is up 77% from its price of ₩7,110 on 07 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 2.0% over the same period. Is New 90 Day High Low • Oct 20
New 90-day high: ₩9,100 The company is up 46% from its price of ₩6,230 on 22 July 2020. The South Korean market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 5.0% over the same period. 
